Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

USPSTF Lowers the Recommended Age for CRC Screenings, Mandating Insurance Coverage

May 18, 2021
By Audrey Sternberg
News
Article

Recommendations published in JAMA are set to change colorectal cancer screening guidance for all individuals in the United States.

An update to the U.S. Preventive Services Task Force (USPSTF) recommendations now indicate that screening for colorectal cancer (CRC) should begin at age 45 years for all patients regardless of baseline characteristics, according to guidelines published in JAMA.1

This is a follow-up to draft guidance that was issued in October 2020 amending the recommended age of screening from 50 to 45 years of age and will mandate insurance coverage of screening for CRC.

These efforts by the task force are in large part a reaction to the alarming rise in the incidence of young-onset CRC, which occurs in patients younger than 50 years of age. By 2040, this is projected to be the leading cause of cancer deaths in patients ages 20 to 49 years.

This increasing incidence has been documented since the 1990s, but the proportion of patients with young-onset disease has accelerated rapidly over the last 10 years, with 11% of colon cancers and 15% of rectal cancers occurring in patients under the age of 50 years in 2020 compared with just 5% and 9%, respectively, in 2010.

“Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed, but we must take bold steps to translate the lowered age of beginning screening into meaningful decreases in CRC incidence and mortality,” Kimmie Ng, MD, MPH, director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute and author of an accompanying editorial, said in a press release.2,3 “Lowering the recommended age to initiate screening will make colorectal cancer screening available to millions more people in the United States, and hopefully many more lives will be saved by catching colorectal cancer earlier, as well as by preventing colorectal cancer.”

Age 45 was selected by the task force based on evidence that averting more early deaths was possible versus starting at age 50 with a relatively small increase in the number of complications from colonoscopy. Of note, the new recommendation does not change guidance regarding screening in older individuals, with patients aged 76 to 85 years recommended for selective screening only.

In the editorial, Ng and colleagues point out that screenings at age 45 will not be enough to catch all cases of early-onset CRC, as the rate of colon cancer shows the steepest increase in patients aged 20 to 29 years at 2% versus 1.3% in those 40 to 49 years. Corresponding rates in rectal cancer were 3.2% and 2.3%, respectively.

“We are now seeing patients even younger than 45—in their 20s and 30s—who are being diagnosed with this cancer and often at very late stages,” Ng said. “Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed.”

With the prior recommendations, less than 70% of patients who were eligible for screening received the preventative benefit, with patients who are uninsured or underinsured, those with lower incomes, and racial and ethnic minorities being disproportionately underserved. CRC is a disease that disproportionately affects African Americans, as they have a 20% greater likelihood of developing the tumor and a 40% greater risk of dying from it. As such, Ng and colleagues said addressing these public health barriers will be necessary to raise screening adherence.

References

1. US Preventive Services Task Force. Screening for Colorectal CancerUS Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238

2. Ng K, May FP, Schrag D. US Preventive Services Task Force Recommendations for Colorectal Cancer ScreeningForty-Five Is the New Fifty. JAMA. 2021;325(19):1943-1945. doi:10.1001/jama.2021.4133

'45 is the new 50' as age for colorectal cancer screening is lowered. News release. Dana-Farber Cancer Institute. May 18, 2021. Accessed May 18, 2021. https://bit.ly/3bBK1DT

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.
Related Content

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 16th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 16th 2025
Podcast

Referrals to dietitians may help in the management of TEAEs affecting taste and smell, as well as fatigue in patients undergoing cancer treatment.

Navigating Nutritional Challenges in Cancer Survivorship and Care

Roman Fabbricatore
September 16th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to the Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
September 16th 2025
Podcast

In the News: Top FDA Meetings, Decisions, and Actions in Cancer Care

In the News: Top FDA Meetings, Decisions, and Actions in Cancer Care

Ariana Pelosci
September 16th 2025
Article

Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.

Encorafenib Triplet Exhibits Early Efficacy in MSS BRAFV600E Metastatic CRC

Roman Fabbricatore
September 16th 2025
Article
Related Content

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 16th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 16th 2025
Podcast

Referrals to dietitians may help in the management of TEAEs affecting taste and smell, as well as fatigue in patients undergoing cancer treatment.

Navigating Nutritional Challenges in Cancer Survivorship and Care

Roman Fabbricatore
September 16th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to the Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
September 16th 2025
Podcast

In the News: Top FDA Meetings, Decisions, and Actions in Cancer Care

In the News: Top FDA Meetings, Decisions, and Actions in Cancer Care

Ariana Pelosci
September 16th 2025
Article

Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.

Encorafenib Triplet Exhibits Early Efficacy in MSS BRAFV600E Metastatic CRC

Roman Fabbricatore
September 16th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.